Shweta Kumar

ID: 1b83a032-2619-30fb-68c4

/

Unclaimed

/

Organization: Goodwin Procter

FDA Accepts for Review Fresenius Kabi’s BLA for Tocilizumab Biosimilar

Big Molecule Watch · August 2, 2022

Formycon Q1 2022 Financial Results and Announcement of Two New Biosimilar Products

Big Molecule Watch · June 28, 2022

EMA Recommends Denying Marketing Authorization for Prestige BioPharma’s TUZNUE and HERVELOUS (trastuzumab)

Big Molecule Watch · May 24, 2022

FDA Approves Amneal’s ALYMSYS (bevacizumab-maly)

Big Molecule Watch · April 20, 2022

JAMA Oncology Publishes Results of Phase III Study for Prestige BioPharma’s HERCEPTIN Biosimilar, HD201

Big Molecule Watch · March 21, 2022